David Marks, MBBS, PhD, FRACP, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, UK, discusses reduced-intensity conditioning protocols for bone marrow transplants in patients with acute lymphoblastic leukemia (ALL). The UKALL14 trial has the largest prospective series of reduced-intensity transplant in adults and shows excellent results with 4-year survival in the order of 54%. In addition, the fludarabine, melphalan, and alemtuzumab regimen was well tolerated. Nonetheless, the results can be improved as relapse remains a challenge. The ALL-RIC study is comparing the fludarabine, melphalan, and alemtuzumab regimen with reduced dose total body irradiation and cyclophosphamide with the aim to reduce relapse and prolong survival. Prof. Marks also discusses the effect of graft-versus-host disease on the outcome of ALL transplanted patients. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.